Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Clear as a bell!

<< Previous

Bullboard Posts

Next >>

Comment by pelabooston Oct 04, 2024 11:02am

82 Views

Post# 36253243

RE:RE:Clear as a bell!

Bucko, you sound a bit disgruntled. Noteable has consistently posted about the possibility of Accelerated Approval in mBC with cogent, clear and concise explanations. Sour grapes is not a good look. Allow credit to be taken. Cheers.

PS. GOBLET could also be exciting with a very broad reach.

<< Previous

Bullboard Posts

Next >>

Calibre discovers significant gold in Newfoundland